Hypofractionated radiotherapy produces similar long-term outcomes as conventionally fractionated radiotherapy in high-risk prostate cancer, a phase 3 study suggests.
Prophylactic radiotherapy of asymptomatic bone metastases can reduce skeletal-related events and improve survival in patients with solid tumors, a study suggests.
Durvalumab plus IMRT proved no more effective than cetuximab plus IMRT in patients with treatment-naïve, locoregionally advanced head and neck squamous cell carcinoma.
Adding stereotactic body radiation therapy to sorafenib improves survival outcomes in patients with advanced hepatocellular carcinoma, a phase 3 trial suggests.